Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant 20 mg Effect on HDL Kinetics in Abdominal Obesity
2006-001716-71Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Abdominal adiposity (ABCD) and Metabolic Syndrome (MetS) comparing Rimonabant 20 mg with Placebo (2 arms). Primary endpoint: Fractional catabolic rate of ApoA-I in HDL after 12 months. Started Jul 2006; status: completed.
02
Drugs
rimonabant
03
Conditions
Abdominal adiposity (ABCD)Metabolic Syndrome (MetS)
Beyond the preview
Go deeper on 2006-001716-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001716-71.